Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS

Table 3

Extraction recovery of atazanavir, darunavir, and ritonavir from human plasma.

QC level	Atazanavir			Darunavir			Ritonavir
	Area response		Extraction recovery, % (B/A)	Area response		Extraction recovery, % (B/A)	Area response		Extraction recovery, % (B/A)
	A	B		A	B		A	B
LQC	9773	9514	97.35	20074	19861	98.94	6074	6118	100.72
MQC-2	104201	102458	98.33	183148	187367	102.30	64148	63283	98.65
MQC-1	1654728	1694608	101.06	2491752	2435246	97.73	390617	384267	98.37
HQC	3382518	3408890	100.16	4922563	4847816	98.48	821547	838931	102.12
QC level	Atazanavir-d6			Darunavir-d9			Ritonavir-d6
	Area response		Extraction recovery, % (B/A)	Area response		Extraction recovery, % (B/A)	Area response		Extraction recovery, % (B/A)
	A	B		A	B		A	B
LQC	338514	335727	99.18	530681	531079	100.07	105065	103329	98.35
MQC-2	348240	339419	97.47	510151	525715	103.05	102738	102443	99.71
MQC-1	341729	346341	101.35	541747	535298	98.81	98827	96357	97.50
HQC	331508	337897	101.93	520571	517827	99.47	97538	99945	102.47

LQC: low quality control; MQC: medium quality control; HQC: high quality control.
A: mean area response of six replicate samples prepared by spiking in extracted blank plasma.
B: mean area response of six replicate samples prepared by extracting spiked blank plasma.